Lana Pine

Patients with PsA in the self-reported racial and ethnic minority were less likely to be diagnosed within 12 months of symptom onset and were more frequently uninsured compared with White patients .

Jawaheer and her team used pre-pregnancy data to determine whether there are gene expression biomarkers at the pre-pregnancy baseline that can predict improvement or worsening during pregnancy in patients with rheumatoid arthritis.

Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.

The study shows rosnilimab's specificity in targeting PD-1 positive T cells, especially the PD-1 high T cells prevalent in inflamed tissues.

Patients with systemic lupus erythematosus exhibited comparable or higher incidence rates of infection in the placebo cohort compared with belimumab.

Severity-dependent anemia and low hemoglobin levels were significant risk factors for stroke/transient ischemic attack and bleeding in patients with atrial fibrillation treated with warfarin.

Research demonstrates eltrombopag is a safe and effective treatment option for patients with refractory or relapsed severe aplastic anemia, with 70% of patients achieving hematologic response at week 26.

At the 7-month mark, multivariate analysis revealed patients with psoriasis aged ≥65 years reported a significantly better response to tildrakizumab.

Results revealed the health plan type highly influenced the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.

Most patients with active Crohn’s disease receiving adalimumab biosimilar, HS016, achieved clinical response at weeks 12, 26, and 52.

Syndesmophyte development was 4 times more probable when patients had a clinical or radiographic description of axial involvement combined with elevated C-reactive protein.

David Charles, MD, highlights how alternative funding programs, though well-intentioned, can inadvertently erode trust between patients and providers and cause delays in healthcare.

David Charles, MD, chief medical officer of the Alliance for Patient Access, delves into the far-reaching implications of alternative funding programs.

Stacie Bell, PhD, discusses the partnership between Lupus Therapeutics and AbbVie for the phase 3 clinical program of upadacitinib in patients with SLE, emphasizing the importance of collaboration and their role in accelerating the study process, recruitment, and the potential for meaningful advancements in lupus treatment.

Rosalind Ramsey-Goldman, MD, discusses her study, “The impact of US abortion policy on rheumatology clinical practice: a cross-sectional survey of rheumatologists.”

V Michael Holers, MD, discusses the creation of Rheumatology Lab in response to a pressing need within the clinical practice community to provide an easily accessible resource for physicians to guide patients to valuable information.

Robert Edwards, PhD, discusses how cognitive behavioral therapy effectively reduced pain catastrophizing and improved quality of life in patients with fibromyalgia.

The FDA has expanded the approval of abatacept (Orencia) for the treatment of active psoriatic arthritis in patients aged 2 years and older.

Ruth Napier, PhD, discusses her study revealing the crucial role the biomarker Card9 plays in the pathogenesis of ankylosing spondylitis.

Guselkumab effectively cleared the skin of patients with moderate-to-severe plaque psoriasis across all skin tones, with significant improvements observed within the first 16 weeks of treatment.

Patients with moderate to severe scalp psoriasis treated with tildrakizumab exhibited sustained efficacy through week 52, demonstrating the long-term effectiveness and safety profile of this treatment.

Patients in the deucravacitinib group had higher response rates compared with placebo at week 16, regardless of the extent of baseline PASI score or BSA involvement.

Patients with scalp and body psoriasis who used nonsteroidal roflumilast foam .3% once daily experienced significant symptom improvement as early as 2 weeks.

Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.

Tildrakizumab significantly improved work productivity and reduced work activity impairment in patients with moderate to severe plaque psoriasis, highlighting this treatment's quality of life benefits.

Secukinumab treatment resulted in greater improvements compared with placebo at week 12, with responses increasing through week 52.

Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.

Linda Stein Gold, MD, explains how the safety considerations of nonsteroidal topicals must be weighed against their significant value in the treatment arsenal.

Linda Stein Gold, MD, discusses the notable transition in topical therapies for both psoriasis and atopic dermatitis, with the introduction of effective FDA-approved nonsteroidal treatments.

April Armstrong, MD, MPH, explains how early detection of psoriatic arthritis and psoriasis is critical to prevent irreversible joint damage and improve patient outcomes.